Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
This was the stock's second consecutive day of losses.
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback